Schering-Plough Opens Research Centre

Schering-Plough Corporation has opened its Translational Medicine Research Centre (TMRC) in Singapore. The TMRC will be part of the Schering-Plough Research Institute (SPRI), the company’s human pharmaceutical research and development arm.

The TMRC will support SPRI’s global research and development programs by focusing on biomarker discovery and development.

The TMRC comprises of a translational research lab (TRL), and a translational medicine unit (TMU) that is scheduled to begin operation later this year. The sites are run by 20 employees and the company expects to add over 50 employees in the next few years.

The focus of the TRL is on biomarker development for all therapy areas: cardiovascular, central nervous system, immunology and infectious diseases, oncology, respiratory and women’s health. In addition, TRL also performs biomarker discovery work in the field of oncology. It also performs non-invasive imaging for the company’s discovery and exploratory clinical development programs.

This facility occupies approximately 30,000 sq ft and is located in the Biopolis biomedical research campus.